Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.56 per share a year ago. These ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

What is the current share price of Werewolf Therapeutics (HOWL)? Werewolf Therapeutics's (HOWL) current share price is $4.72. This constitutes a price movement of 14.95% when compared to the share ...

Werewolf Therapeutics Reports Prelim Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an ...

In a challenging turn for Werewolf Therapeutics, the biotechnology firm's stock has plummeted to a 52-week low, trading at $1.25.

"A man might befriend a wolf, even break a wolf, but no man could truly tame a wolf."― George R.R. Martin, A Dance with Dragons Today, we take our first look at a small biotech name with a memorable ...